The 2026 flu vaccine features two new strains replacing both influenza A components from 2025.
Australia shifts to trivalent vaccines this year after removing the B/Yamagata lineage strain. This marks the first change since quadrivalent vaccines became standard in 2016.
The Australian Influenza Vaccine Committee recommended these updates in October 2025 following WHO guidance. The Therapeutic Goods Administration accepted the recommendations for vaccines available from April 2026.
Understanding what changed helps Australians make informed vaccination decisions for the upcoming flu season.
New Strains in the 2026 Vaccine
The 2026 southern hemisphere trivalent vaccine includes completely new H1N1 and H3N2 strains. These updates respond to significant viral evolution throughout 2025.
For H1N1, the vaccine now contains A/Tasmania/503/2024 (H1N1)pdm09-like virus. The H3N2 component differs based on production method.
Egg-based vaccines use A/Singapore/GP20238/2024 (H3N2)-like virus. Cell-based vaccines contain A/Sydney/1359/2024 (H3N2)-like virus. This marks the first time different H3N2 strains exist for different production methods.
The B/Victoria lineage remains unchanged from 2025. It continues using B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
The B/Yamagata lineage disappeared from global circulation after March 2020. No naturally occurring cases have been confirmed since then. This extremely low infection risk prompted removal from vaccine formulations.
The shift to trivalent vaccines reduces costs without compromising protection. The eliminated strain no longer poses a public health threat.
The Super-K Variant Challenge
Subclade K emerged unexpectedly late in Australia’s 2025 flu season. This H3N2 variant appeared in September rather than typical winter months.
Cases remained elevated through spring and summer. The Doherty Institute reported 2025 represented one of the longest flu seasons on record.
Super-K contains substantial mutations in the hemagglutinin protein. This protein helps the virus attach to cells. Mutations create antigenic mismatch with 2025 vaccine antibodies.
Early data showed reduced vaccine effectiveness against subclade K infections. However, vaccinated people experienced approximately 56 per cent less likelihood of GP visits and 49 per cent reduced hospitalization risk compared to unvaccinated individuals.
The 2026 vaccine addresses this mismatch. Updated H3N2 components specifically target subclade K characteristics. This should restore optimal protection levels.
Professor Patrick Reading from the WHO Collaborating Centre noted it represents a race to update vaccines. The goal gives immune responses the best chance of effective protection during flu season.
Intranasal Vaccine Option for Children
FluMist received TGA registration for Australian use in December 2025. This live attenuated influenza vaccine provides needle-free administration for children aged 2 to 17 years.
Four states announced free FluMist programs starting in 2026. New South Wales, Queensland, and South Australia offer it free for children aged 2 to under 5 years. Western Australia extends coverage to children aged 2 to under 12 years.
The vaccine delivers via quick nasal spray into both nostrils. It absorbs rapidly and works even if children sneeze afterward. The National Centre for Immunisation Research and Surveillance confirms FluMist provides protection equivalent to injectable vaccines.
FluMist contains weakened flu virus strains. These cannot cause influenza but train the immune system to recognize threats. Millions of doses have been safely administered in the UK and USA over the past decade.
Common side effects include runny or blocked nose, headache, and tiredness. These effects are mild and short-lived. Serious reactions like anaphylaxis remain extremely rare.
Children with certain medical conditions may require injectable vaccines instead. ATAGI will release final recommendations early in 2026.
Who Should Get Vaccinated in 2026
Everyone over six months of age should receive annual flu vaccination. Protection wanes over time and circulating strains change yearly.
Free vaccination under the National Immunisation Program covers specific high-risk groups. This includes children aged 6 months to under 5 years, pregnant women, people aged 65 and over, Aboriginal and Torres Strait Islander people, and individuals with medical conditions increasing severe flu risk.
The 2025 season saw high case numbers. Australia reported 502,493 influenza notifications. Cases extended beyond typical winter months into late spring.
Vaccination takes approximately two weeks to build protective immunity. The Australian Government Department of Health and Aged Care recommends vaccination before peak flu season beginning in May.
Protection remains strongest for three to four months after vaccination. Timing matters for optimal coverage through peak winter months.
Vaccine Effectiveness Considerations
No flu vaccine provides 100 per cent protection against infection. Effectiveness typically ranges from 70 to 90 per cent in healthy adults.
Multiple factors influence protection levels. Vaccine-virus match, individual immune response, and circulating strain dominance all matter. Age and underlying health conditions also affect outcomes.
The 2025 season demonstrated vaccines still provide meaningful protection despite antigenic mismatch. Vaccinated individuals experienced significantly reduced severe disease and hospitalization rates.
Enhanced vaccines exist for older adults. Fluad Quad contains an adjuvant boosting immune responses in people aged 65 and over. This addresses age-related immune decline affecting vaccine effectiveness.
Cell-based production methods benefit people with egg allergies. Flucelvax Quad is registered for use in people from six months of age.
Preparing for the 2026 Season
Flu vaccines typically become available in Australian clinics from late March through early April. Most vaccination occurs between April and June for optimal winter coverage.
Book appointments early to avoid peak demand periods. General practices, pharmacies, and community immunization providers offer flu vaccines.
Some workplaces provide onsite flu vaccination clinics. These convenient programs increase coverage rates while minimizing disruption.
Check eligibility for free vaccines through the NIP. Eligible groups receive vaccines at no cost through participating providers.
Private purchase options exist for people outside NIP eligibility. Costs vary between providers but typically range from $20 to $40. The Heart Foundation recommends flu vaccination for people with cardiovascular disease as influenza increases heart attack and stroke risk.
Conclusion
The 2026 flu vaccine includes two new influenza A strains responding to significant viral evolution in 2025. Australia transitions to trivalent vaccines after removing the extinct B/Yamagata lineage component. The updated formulation specifically addresses the challenging subclade K variant that extended the 2025 flu season well beyond typical winter months.
New intranasal vaccine options for children and enhanced formulations for older adults expand vaccination accessibility. Annual vaccination remains the most effective protection against serious influenza illness and complications. For more information about protecting your health this winter, visit our guide to respiratory illness prevention.
FAQs
1. Why did Australia switch from quadrivalent to trivalent flu vaccines?
The B/Yamagata influenza lineage has not circulated naturally since March 2020. Global surveillance confirms extinction risk is extremely low. Removing this unnecessary component from vaccines reduces manufacturing costs without compromising protection against circulating strains.
2. Is the 2026 vaccine effective against the Super-K variant?
Yes. The updated H3N2 component specifically targets subclade K characteristics that caused extended circulation in 2025. This addresses the antigenic mismatch that reduced 2025 vaccine effectiveness while maintaining protection against other circulating strains.
3. Can my child get the nasal spray vaccine instead of an injection?
Children aged 2 to under 5 years in NSW, Queensland, and South Australia qualify for free FluMist. Western Australia covers children aged 2 to under 12 years. Children with certain medical conditions may require injectable vaccines instead. Consult your GP about the best option.
4. When is the best time to get vaccinated?
April through early June provides optimal timing. This builds immunity before peak flu season while ensuring protection lasts through winter months. Vaccination takes two weeks to develop full protection and remains strongest for three to four months.
5. Do I need a flu shot if I got one last year?
Yes. Influenza viruses change constantly and vaccine formulations update annually. The 2026 vaccine contains two completely new strains not included in 2025 vaccines. Additionally, immune protection from previous vaccination wanes over time, making annual vaccination essential for continued protection.